OptimizeRx (OPRX) Competitors $12.70 -0.58 (-4.37%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$12.70 +0.01 (+0.04%) As of 07/11/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock OPRX vs. TIXT, EEX, IBTA, NEO, WLDN, NXTT, IIIV, PRSU, NRDS, and RSKDShould you be buying OptimizeRx stock or one of its competitors? The main competitors of OptimizeRx include Telus Digital (TIXT), Emerald (EEX), Ibotta (IBTA), NeoGenomics (NEO), Willdan Group (WLDN), Next Technology (NXTT), i3 Verticals (IIIV), Pursuit Attractions and Hospitality (PRSU), NerdWallet (NRDS), and Riskified (RSKD). These companies are all part of the "business services" industry. OptimizeRx vs. Its Competitors Telus Digital Emerald Ibotta NeoGenomics Willdan Group Next Technology i3 Verticals Pursuit Attractions and Hospitality NerdWallet Riskified Telus Digital (NYSE:TIXT) and OptimizeRx (NASDAQ:OPRX) are both small-cap computer and technology companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment and dividends. Which has more volatility and risk, TIXT or OPRX? Telus Digital has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, OptimizeRx has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500. Is TIXT or OPRX more profitable? Telus Digital has a net margin of -4.27% compared to OptimizeRx's net margin of -16.33%. Telus Digital's return on equity of 3.40% beat OptimizeRx's return on equity.Company Net Margins Return on Equity Return on Assets Telus Digital-4.27% 3.40% 1.48% OptimizeRx -16.33%-0.29%-0.20% Do analysts rate TIXT or OPRX? Telus Digital presently has a consensus price target of $4.05, suggesting a potential upside of 7.89%. OptimizeRx has a consensus price target of $10.81, suggesting a potential downside of 14.86%. Given Telus Digital's higher probable upside, equities research analysts clearly believe Telus Digital is more favorable than OptimizeRx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telus Digital 2 Sell rating(s) 12 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.12OptimizeRx 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.73 Which has higher valuation and earnings, TIXT or OPRX? OptimizeRx has lower revenue, but higher earnings than Telus Digital. OptimizeRx is trading at a lower price-to-earnings ratio than Telus Digital, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTelus Digital$2.66B0.39-$61M-$0.49-7.65OptimizeRx$92.13M2.55-$18.66M-$0.84-15.12 Do institutionals and insiders believe in TIXT or OPRX? 59.6% of Telus Digital shares are held by institutional investors. Comparatively, 76.5% of OptimizeRx shares are held by institutional investors. 4.8% of Telus Digital shares are held by company insiders. Comparatively, 5.6% of OptimizeRx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media favor TIXT or OPRX? In the previous week, Telus Digital had 1 more articles in the media than OptimizeRx. MarketBeat recorded 3 mentions for Telus Digital and 2 mentions for OptimizeRx. OptimizeRx's average media sentiment score of 0.75 beat Telus Digital's score of 0.61 indicating that OptimizeRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telus Digital 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OptimizeRx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryTelus Digital beats OptimizeRx on 9 of the 17 factors compared between the two stocks. Get OptimizeRx News Delivered to You Automatically Sign up to receive the latest news and ratings for OPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OPRX vs. The Competition Export to ExcelMetricOptimizeRxCOMP IndustryComputer SectorNASDAQ ExchangeMarket Cap$245.62M$163.09B$27.76B$9.11BDividend YieldN/A1.28%3.11%4.02%P/E Ratio-15.1236.8436.8320.25Price / Sales2.5517.441,883.2599.61Price / CashN/A28.3738.1558.16Price / Book2.009.717.275.49Net Income-$18.66M$3.58B$767.31M$250.27M7 Day Performance-6.27%-1.87%-0.22%4.75%1 Month Performance-15.61%6.87%4.07%7.64%1 Year Performance24.63%44.37%52,050.70%16.34% OptimizeRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OPRXOptimizeRx1.7356 of 5 stars$12.70-4.4%$10.81-14.9%+28.0%$245.62M$92.13M-15.12100TIXTTelus Digital1.7072 of 5 stars$3.63+0.8%$4.05+11.5%-40.8%$992.34M$2.66B-7.4178,879News CoverageAnalyst UpgradeEEXEmerald1.6017 of 5 stars$4.86-1.6%$7.90+62.6%-3.1%$982.36M$398.80M162.05600IBTAIbotta3.1271 of 5 stars$36.63-0.9%$61.60+68.2%N/A$935.47M$367.25M24.75N/AGap DownNEONeoGenomics3.4774 of 5 stars$7.31+1.8%$13.83+89.2%-49.4%$924.03M$660.57M-11.982,200WLDNWilldan Group4.0594 of 5 stars$62.51+0.3%$51.50-17.6%+130.9%$903.15M$565.80M36.991,761News CoverageAnalyst ForecastNXTTNext Technology1.1977 of 5 stars$2.30+12.7%N/A-48.2%$889.98M$1.80M0.008Positive NewsIIIVi3 Verticals3.5437 of 5 stars$27.48+4.0%$29.57+7.6%+26.8%$878.09M$229.92M6.251,480News CoveragePRSUPursuit Attractions and Hospitality0.9687 of 5 stars$28.80-0.4%$29.67+3.0%N/A$817.16M$366.49M24.101,500Positive NewsNRDSNerdWallet3.4987 of 5 stars$10.97+0.4%$15.00+36.7%-27.7%$814.42M$687.60M28.13770News CoverageRSKDRiskified1.4961 of 5 stars$5.00+0.6%$6.03+20.6%-19.7%$801.21M$327.52M0.00780Positive News Related Companies and Tools Related Companies Telus Digital Alternatives Emerald Alternatives Ibotta Alternatives NeoGenomics Alternatives Willdan Group Alternatives Next Technology Alternatives i3 Verticals Alternatives Pursuit Attractions and Hospitality Alternatives NerdWallet Alternatives Riskified Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OPRX) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OptimizeRx Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share OptimizeRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
